AstraZeneca has announced new medicines and emerging markets have driven its growth in the first half (H1) of 2018. This has been partially offset by the loss of Crestor exclusivity in Europe and Japan.
The new drug R&D level further improves in China with the development of the pharmaceutical technology, technological innovation has become the key part in the pharmaceutical industry development...
During the release of Q3 figures, GlaxoSmithKline’s CEO, Emma Walmsley, revealed that the company would consider making moves to bolster its healthcare unit, even as other companies look to slim down.